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ABSTRACT
Sleep disorders are the common side effects of beta blockers. Beta blockers have been shown to reduce the 
production of melatonin via specific inhibition of adrenergic beta1-receptors. Exogenous melatonin, taken 
in the evening as a supplement, could reduce the central nervous system  (CNS) side effects (sleep disorder) 
associated with beta-adrenergic receptor blockers as well as the potential risk associated with reduction of the 
melatonin synthesis.
Key words: Beta blockers, hypertension, melatonin
Night-time exogenous melatonin administration may be a 
beneficial treatment for sleeping disorders in beta blocker patients 
Auda Fares
Department of Internal Medicine, S. Johannes Hospital, Germany
Address for correspondence: Dr. Auda Fares, Department of Internal Medicine, Albert-Schlangen  
Str. 36 50181, Bedburg, Germany. E-mail: audafares@yahoo.com
Review Article JCDR
with either vasoconstrictor or vasodilatory effects of 
melatonin.[4] Synthesis and release of melatonin are 
stimulated by norepinephrine via beta1-adrenoceptors 
and this process is further potentiated by stimulation of 
alpha1-adrenoceptors.[5] Beta blockers have been shown to 
reduce the production of melatonin via specific inhibition 
of beta-1 adrenergic receptors. Results of two placebo-
controlled studies of hypertensive patients, investigating 
the relationship between beta blocker induced central 
nervous system (CNS) side effects and the nightly urinary 
excretion of melatonin, demonstrated that the CNS side 
effects (sleep disorder, nightmares) during beta blockade are 
related to a reduction of melatonin levels.[6] Similar findings 
have been found in case–control study of six patients with 
nightmares and hallucinations during treatment with beta-
adrenoceptor blocking agents compared to six control 
patients with similar diagnoses and treatment but without 
such symptoms of the CNS. Nightly melatonin excretion 
was lower in all cases with nightly CNS symptoms than in 
the control patients.[7] Since sleep disturbances are common 
side effects of beta blockers and lower nocturnal melatonin 
levels might be the reason for this disorder, nighttime 
exogenous administration of melatonin might avoid this 
well-known side effect of beta blockers.
MELATONIN AND HYPERTENSION
The involvement of melatonin in the regulation of arterial 
Access this article online
Quick Response Code:
Website:
www.jcdronline.com
DOI:
10.4103/0975-3583.85261 
INTRODUCTION
Beta-adrenergic receptor blockers are an important class of 
drugs in the management of patients with cardiovascular 
diseases. Incidence of both acute and chronic heart diseases 
systematically is age dependent.[1] Beta blockers often are 
not well tolerated, and the compliance rates with these 
medications are dismal. In a meta-analysis of  randomized 
controlled trials, the risk of treatment withdrawal was 
80% and 41% greater with beta blockers compared with 
diuretics and renin–angiotensin–aldosterone system 
(RAAS) blockers, respectively.[2] In contrast, melatonin 
concentrations in serum, as well as the urinary levels of 
its main metabolite, 6-sulfatoxymelatonin, are lower in 
older, when compared to the values observed in younger 
population.[3] Extensive epidemiological evidence and 
experimental animal studies suggest that melatonin exerts 
certain effects upon the cardiovascular system. The 
presence of vascular melatoninergic receptors has been 
demonstrated; these receptors are functionally associated 154 Journal of Cardiovascular Disease Research Vol. 2 / No 3
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blood pressure and heart rate has been implicated in several 
studies.[8,9] Melatonin administration has been shown 
to induce a hypotensive effect in both normotensive[7] 
and spontaneously hypertensive rats.[10,11] A lowering of 
arterial blood pressure has also been reported from an 
uncontrolled study on essential hypertensive patients.[12] A 
crossover, placebo-controlled study evaluating the effects 
of the evening intake of melatonin by young and healthy 
normotensive subjects[13] showed a mild hypotensive effect 
during the whole 24-hour period, with a concomitant heart 
rate lowering during the diurnal hours. In another crossover 
study, 16 men with essential hypertension given melatonin 
for 3 weeks, 1 hour before sleep onset, exhibited reduced 
nocturnal systolic and diastolic blood pressures by 6 and 4 
mm Hg, respectively.[14] Pinealectomy enhances the vascular 
reactivity to vasoconstrictive agents,[15] which can be reversed 
by melatonin.[16] The mechanisms whereby melatonin 
influences blood pressure could involve any of the following: 
(i) a direct effect on neural centers governing cardiovascular 
status; (ii) reduction in catecholamine concentrations; 
(iii) relaxing smooth muscle in blood vessels; and (iv) 
antioxidative actions. The ability of melatonin to modulate 
blood pressure may be a result of both receptor-mediated 
and receptor-independent processes.
MELATONIN AND DRUG INTERACTION
Several studies have assessed the possible interaction of 
melatonin with other drugs on human subjects. One study 
reported that the non-selective beta blocker (carvedilol) 
and calcium channel blockers (Verapamil) do not decrease 
nocturnal melatonin production,[17] while another study 
showed that chronic evening ingestion of melatonin 
in hypertensive patients, well controlled by nifedipine 
gastrointestinal therapeutic system (GITS), induces a 
BP increase and a heart rate acceleration. Kinetic or 
pharmacodynamic interaction between melatonin and 
nifedipine is able to impair the antihypertensive efficacy 
of the calcium channel blocker.[18] This study suggests that 
the pineal hormone might interfere with calcium channel 
blocker therapy. Another study revealed that combination of 
angiotensin II receptor antagonist (losartan) and melatonin 
reduced BP more noticeably than losartan alone.[19] Recently, 
this group also showed that combination of moxonidine and 
melatonin is more effective on hemodynamic parameters in 
patients with arterial hypertension than moxonidine alone.[20]
CARDIOPROTECTIVE EFFECTS OF MELATONIN
Melatonin has been shown to have anti-anginal and 
anti-ischemic effects, to improve the contractile function 
following myocardial ischemia-reperfusion and also to 
act against oxidative damage induced by other free radical   
generating agents.[21,22] Recent evidence reveals that the 
patients with coronary heart disease, especially those 
with higher risk of cardiac infarction and/or of sudden 
death, have a low melatonin production rate. It has also 
been reported that people with high levels of low-density 
lipoprotein (LDL)-cholesterol have low levels of melatonin. 
It has been shown that melatonin suppresses the formation 
of cholesterol, reduces LDL accumulation in serum,[23] and 
modifies fatty acid composition of rat plasma and liver 
lipids.[24] However, the effects of a therapy modulating the 
melatoninergic system on cardiovascular hemodynamics 
and rhythmicity under several physiopathological conditions 
need to be further explored, together with the possible 
impact on cardiovascular morbidity and mortality.[4]
INFLUENCE OF MELATONIN ON COGNITIVE AND 
SLEEPING
Several studies have shown that the sleep patterns in elderly 
insomniacs are improved by the administration of 2 mg 
of melatonin.[25] A recent study has shown the positive 
effects of administration of 0.3 mg of melatonin in the 
late evening on sleep pattern in older people.[26] In one 
placebo-controlled crossover study of 10 elderly subjects 
with mild cognitive impairment, treatment with 6 mg 
of melatonin led to improve sleep, memory, and mood 
in the elderly.[27] Melatonin administration at a dose of   
1 mg nightly may be effective in improving certain aspects of 
cognitive functioning and subjective reports of sleep quality in 
elderly subjects. It may prove to be a useful therapeutic agent 
in the treatment of age-related cognitive decline. Another 
intriguing aspect of the melatonin–sleep relationship is the 
effect of melatonin on dream quality and content. One study 
reported that oral administration of 250 mg of melatonin 
facilitated subjects’ dreaming and increased the number of 
rapid eye movements during REM sleep.[28] Another study 
showed an increase in dreaming or the occurrence of more 
vivid dream after ingesting 0.3 mg dose of melatonin.[27]
POTENTIAL RISK ASSOCIATED WITH MELATONIN 
DEFICIENCY
Melatonin deficiency may be a critical starting point for 
the degenerative processes leading to cellular pathology 
and oncogenesis. Several studies have demonstrated a 
link between decreased melatonin synthesis and cancer. 
One study reported that women with breast cancer have 
lower levels of melatonin than those without the disease. 
Laboratory experiments indicate that lower levels of 
melatonin stimulate the growth of breast cancer cells.[29] 
Another study revealed that colorectal cancer patients had 155 Journal of Cardiovascular Disease Research Vol. 2 / No 3
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lower plasma levels of melatonin than healthy control 
subjects, suggesting a possible link between low melatonin 
levels and the enhanced development of colorectal cancer in 
humans.[30,31] Recently, melatonin has been implicated in the 
pathogenesis and clinical course of multiple sclerosis. When 
melatonin levels decline, an exacerbation of MS symptoms 
is seen.[32] In another study, a significant correlation between 
melatonin deficiency and endometrial cancer was found.[33] 
Melatonin is reduced by two thirds in patients with prostate 
cancer as compared with those who have benign prostate 
disease.[34] Therefore, a relative melatonin deficiency at the 
cellular level, induced by beta blockers, might increase the 
cancer risk. Furthermore, beta-adrenoceptor blockers, which 
depress melatonin secretion, exert immunosuppressive 
effects when given in the evening. Exogenous melatonin 
reverses beta blocker induced immunosuppression and 
enhances immune parameters in animals.[34]
CONCLUSION
Exogenous melatonin taken in the evening as a supplement 
could reduce the CNS side effects (sleep disorder) associated 
with beta-adrenergic receptor blockers as well as the 
potential risk associated with reduction of the melatonin 
synthesis. However, the optimal use of melatonin in 
hormone replacement therapy requires that the patient 
recieve the correct dose at the proper time. A lack of 
documented negative side effects does not mean an absence 
of such effects. Long-term clinical and experimental studies 
are needed to address this important question.
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